1. Home
  2. NVCR
  3. NVCR News

Latest NovoCure Limited (NVCR) News on October 8, 2025

Novocure to Report Third Quarter 2025 Financial Results
NVCR

Business Wire

7 days ago

Novocure to Report Third Quarter 2025 Financial Results

Insider Spends US$997k Buying More Shares In NovoCure
NVCR

Simply Wall St.

a month ago

Insider Spends US$997k Buying More Shares In NovoCure

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer
NVCR

Zacks

2 months ago

NVCR Stock Slips Despite PMA Application to Treat Pancreatic Cancer

NVCR

MT Newswires

2 months ago

NovoCure Submits FDA Premarket Approval Application for Tumor Treating Files Therapy for Pancreatic Cancer

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
NVCR

Business Wire

2 months ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

What Makes NovoCure (NVCR) a New Buy Stock
NVCR

Zacks

4 months ago

What Makes NovoCure (NVCR) a New Buy Stock

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial
NVCR

Zacks

4 months ago

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

NVCR

MT Newswires

4 months ago

Novocure Insider Sold Shares Worth $528,413, According to a Recent SEC Filing

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
NVCR

Benzinga

4 months ago

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
NVCR

Business Wire

4 months ago

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
NVCR

Motley Fool

4 months ago

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street

Novocure Announces Upcoming Investor Events
NVCR

Business Wire

4 months ago

Novocure Announces Upcoming Investor Events

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?
NVCR

Zacks

5 months ago

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?

Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?
NVCR

Zacks

5 months ago

Wall Street Analysts See a 91.92% Upside in NovoCure (NVCR): Can the Stock Really Move This High?

Why NovoCure Stock Skyrocketed This Week
NVCR

Motley Fool

5 months ago

Why NovoCure Stock Skyrocketed This Week

Why NovoCure Stock Leaped 4% Higher Today
NVCR

Motley Fool

5 months ago

Why NovoCure Stock Leaped 4% Higher Today

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
NVCR

Zacks

5 months ago

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

NVCR

MT Newswires

5 months ago

NovoCure's Q1 Loss Narrows, Revenue Rises

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates
NVCR

Zacks

5 months ago

NovoCure (NVCR) Reports Q1 Loss, Tops Revenue Estimates

NVCR

Associated Press Finance

5 months ago

NovoCure: Q1 Earnings Snapshot

Novocure Reports First Quarter 2025 Financial Results
NVCR

Business Wire

5 months ago

Novocure Reports First Quarter 2025 Financial Results

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
NVCR

Business Wire

5 months ago

Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting

Novocure’s device for metastatic NSCLC treatment gains CE Mark
NVCR

Medical Device Network

5 months ago

Novocure’s device for metastatic NSCLC treatment gains CE Mark

NVCR

MT Newswires

6 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release
NVCR

Zacks

6 months ago

Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Q1 Release

NVCR

MT Newswires

6 months ago

NovoCure Says Optune Lua Device Gets CE Mark to Treat Lung Cancer

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
NVCR

Business Wire

6 months ago

Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NVCR

Zacks

6 months ago

NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Why NovoCure Stock Was Withering on Wednesday
NVCR

Motley Fool

6 months ago

Why NovoCure Stock Was Withering on Wednesday

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?
NVCR

Zacks

6 months ago

Strength Seen in Bio-Techne (TECH): Can Its 10.8% Jump Turn into More Strength?

Novocure to Report First Quarter 2025 Financial Results
NVCR

Business Wire

6 months ago

Novocure to Report First Quarter 2025 Financial Results

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
NVCR

Business Wire

7 months ago

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

NVCR

MT Newswires

7 months ago

Novocure Insider Sold Shares Worth $266,126, According to a Recent SEC Filing

NVCR

MT Newswires

7 months ago

Novocure Insider Sold Shares Worth $296,257, According to a Recent SEC Filing

NovoCure Full Year 2024 Earnings: EPS Misses Expectations
NVCR

Simply Wall St.

7 months ago

NovoCure Full Year 2024 Earnings: EPS Misses Expectations

NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...
NVCR

GuruFocus.com

7 months ago

NovoCure Ltd (NVCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Financial ...

NovoCure (NVCR) Q4 2024 Earnings Call Transcript
NVCR

Motley Fool

7 months ago

NovoCure (NVCR) Q4 2024 Earnings Call Transcript

NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
NVCR

Zacks

7 months ago

NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say

NVCR

MT Newswires

7 months ago

NovoCure's Q4 Loss Widens, Revenue Rises

NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
NVCR

Zacks

7 months ago

NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates

NVCR

Associated Press Finance

7 months ago

NovoCure: Q4 Earnings Snapshot

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
NVCR

Business Wire

7 months ago

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NVCR

Zacks

8 months ago

NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’
NVCR

Insider Monkey

8 months ago

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’

NVCR

MT Newswires

9 months ago

NovoCure Opens New Global Headquarters in Switzerland

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
NVCR

Business Wire

9 months ago

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain
NVCR

Simply Wall St.

9 months ago

Investing in NovoCure (NASDAQ:NVCR) a year ago would have delivered you a 85% gain

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
NVCR

Business Wire

9 months ago

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
NVCR

Business Wire

9 months ago

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure price target raised to $42 from $28 at Piper Sandler
NVCR

TipRanks

10 months ago

Novocure price target raised to $42 from $28 at Piper Sandler

Why NovoCure Stock Was Winning Big This Week
NVCR

Motley Fool

10 months ago

Why NovoCure Stock Was Winning Big This Week

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
NVCR

Motley Fool

10 months ago

Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?

Novocure Stock Earns 96 RS Rating
NVCR

Investor's Business Daily

10 months ago

Novocure Stock Earns 96 RS Rating

NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
NVCR

Zacks

10 months ago

NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint
NVCR

TipRanks

10 months ago

Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint

Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds
NVCR

Investor's Business Daily

10 months ago

Novocure Launches 49% After Pancreatic Cancer Treatment Succeeds

Novocure seeks approval after pancreatic cancer wearable scores at Phase III
NVCR

Clinical Trials Arena

10 months ago

Novocure seeks approval after pancreatic cancer wearable scores at Phase III

Novocure seeks approval after pancreatic cancer wearable scores at Phase III
NVCR

Medical Device Network

10 months ago

Novocure seeks approval after pancreatic cancer wearable scores at Phase III

NVCR

MT Newswires

10 months ago

Update: NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
NVCR

Benzinga

10 months ago

NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients

Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success
NVCR

GuruFocus.com

10 months ago

Novocure's Stock Skyrockets Over 32% Amid Groundbreaking Pancreatic Cancer Therapy Success

Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds
NVCR

Investor's Business Daily

10 months ago

Novocure Launches 40% After Pancreatic Cancer Treatment Succeeds

NVCR

MT Newswires

10 months ago

Zai Lab, NovoCure Say Pancreatic Cancer Trial Meets Primary Endpoint

NVCR

MT Newswires

10 months ago

Evercore ISI Upgrades NovoCure to Outperform

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
NVCR

Business Wire

10 months ago

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
NVCR

Business Wire

10 months ago

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in Upcoming Investor Conferences
NVCR

Business Wire

10 months ago

Novocure to Participate in Upcoming Investor Conferences

Novocure secures FDA approval for add-ons to brain cancer treatment wearable
NVCR

Medical Device Network

a year ago

Novocure secures FDA approval for add-ons to brain cancer treatment wearable

NVCR

MT Newswires

a year ago

NovoCure Gets FDA Nod for Updated Optune Gio Arrays

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
NVCR

Business Wire

a year ago

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
NVCR

Business Wire

a year ago

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

NovoCure’s Strong Q3 and Leadership Changes in 2024
NVCR

TipRanks

a year ago

NovoCure’s Strong Q3 and Leadership Changes in 2024

NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...
NVCR

GuruFocus.com

a year ago

NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ...

NovoCure (NVCR) Q3 2024 Earnings Call Transcript
NVCR

Motley Fool

a year ago

NovoCure (NVCR) Q3 2024 Earnings Call Transcript

NVCR

MT Newswires

a year ago

NovoCure Names New Chief Financial Officer

NVCR

MT Newswires

a year ago

NovoCure Q3 Loss Narrows, Net Revenue Increases

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NVCR

Zacks

a year ago

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

NVCR

Associated Press Finance

a year ago

NovoCure: Q3 Earnings Snapshot

Novocure Appoints Christoph Brackmann as Chief Financial Officer
NVCR

Business Wire

a year ago

Novocure Appoints Christoph Brackmann as Chief Financial Officer

Novocure Reports Third Quarter 2024 Financial Results
NVCR

Business Wire

a year ago

Novocure Reports Third Quarter 2024 Financial Results

Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment
NVCR

GuruFocus.com

a year ago

Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment

NovoCure scoops FDA approval on wearable for metastatic cancer treatment
NVCR

Clinical Trials Arena

a year ago

NovoCure scoops FDA approval on wearable for metastatic cancer treatment

NVCR

Medical Device Network

a year ago

NovoCure scoops FDA approval on wearable for metastatic cancer treatment

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.
NVCR

Investor's Business Daily

a year ago

Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.

NVCR

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Premarket Wednesday

NVCR

MT Newswires

a year ago

Sector Update: Health Care

Novocure wins FDA approval for electric field device in lung cancer
NVCR

BioPharma Dive

a year ago

Novocure wins FDA approval for electric field device in lung cancer

NVCR

MT Newswires

a year ago

Top Premarket Gainers

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients
NVCR

Benzinga

a year ago

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

NVCR

MT Newswires

a year ago

HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24

NVCR

Investing.com

a year ago

Novocure shares soar 33% as FDA approves lung cancer treatment

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?
NVCR

Zacks

a year ago

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
NVCR

Investor's Business Daily

a year ago

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment

NVCR

MT Newswires

a year ago

NovoCure Says US FDA Approves Optune Lua to Treat Lung Cancer; Shares Jump After Hours

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
NVCR

Business Wire

a year ago

FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

Novocure to Report Third Quarter 2024 Financial Results
NVCR

Business Wire

a year ago

Novocure to Report Third Quarter 2024 Financial Results

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
NVCR

Business Wire

a year ago

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

Why NovoCure Stock Dived by 13% This Week
NVCR

Motley Fool

a year ago

Why NovoCure Stock Dived by 13% This Week

NVCR

MT Newswires

a year ago

NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor

Novocure Announces Planned CEO Transition
NVCR

Business Wire

a year ago

Novocure Announces Planned CEO Transition

Share on Social Networks: